Radium-223(Ra-223) safety and efficacy in prostate cancer with bone metastases: phase 3 ALSYMPCA study findings stratified by age

被引：0
|
作者：
Sartor, Oliver [1 ]
Coleman, Robert [2 ]
Nilsson, Sten [3 ]
Heinrich, Daniel [4 ]
Staudacher, Karin
Garcia-Vargas, Jose
Vogelzang, Nicholas [5 ]
机构：
[1] Tulane Univ, Ctr Canc, New Orleans, LA 70118 USA
[2] Weston Pk Hosp, Sheffield, S Yorkshire, England
[3] Karolinska Univ Hosp, Stockholm, Sweden
[4] Akershus Univ Hosp, Nordbyhagen, Norway
[5] Comprehens Canc Ctr Nevada, Las Vegas, NV USA
来源：
BJU INTERNATIONAL | 2013年 / 112卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：15 / 16
页数：2
相关论文
共 50 条
  • [1] Radium-223 dichloride (Ra-223) efficacy and safety in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Phase 3 ALSYMPCA study findings stratified by age group
    Wiechno, P.
    Helle, S. I.
    Logue, J.
    Nilsson, S.
    Sartor, O.
    Coleman, R. E.
    Kliment, J.
    Fang, F.
    Parker, C.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S690 - S691
  • [2] Radium-223 dichloride (Ra-223) efficacy and safety in patients with castration-resistant prostate cancer (CRPC) with bone metastases: Phase 3 ALSYMPCA study findings stratified by age group
    Wedel, S.
    Wiechno, P.
    Helle, S., I
    Logue, J.
    Nilsson, S.
    Sartor, O.
    Coleman, R. E.
    Kliment, J.
    Fang, F.
    Parker, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 86 - 87
  • [3] Safety of cytotoxic chemotherapy following Radium-223 Chloride (Ra-223) therapy in the phase 3 alsympca study in patients with Castration-resistant Prostate Cancer (CRPC) with Bone Metastases
    Stroelin, P.
    Sartor, O.
    Coleman, R. E.
    Nilsson, S.
    Vogelzang, N.
    Cross, A.
    Tear, C. G. O'Bryan
    Staudacher, K.
    Vargas, J. E. Garcia
    Zou, J.
    Parker, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 60 - 60
  • [4] SAFETY OF CYTOTOXIC CHEMOTHERAPY FOLLOWING RADIUM-223 CHLORIDE (RA-223) THERAPY IN THE PHASE 3 ALSYMPCA STUDY IN PATIENTS WITH CASTRATION-RESISTANT PROSTATE CANCER (CRPC) WITH BONE METASTASES
    Sartor, O.
    Coleman, R. E.
    Nilsson, S.
    Vogelzang, N.
    Cross, A.
    O'Bryan-Tear, G.
    Staudacher, K.
    Garcia-Vargas, J. E.
    Zou, J.
    Parker, C.
    ANNALS OF ONCOLOGY, 2012, 23 : 308 - 309
  • [5] Hematologic Safety Profile of Radium-223 Dichloride (Ra-223) From the Phase 3 ALSYMPCA Trial in Castration-Resistant Prostate Cancer (CRPC) Patients With Bone Metastases
    Widmark, A.
    Helle, S. I.
    James, N.
    Larsson, A.
    Staudacher, K.
    Haugen, I.
    Garcia-Vargas, J.
    Nilsson, S.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2013, 40 : S189 - S190
  • [6] Pain analyses from the phase 3 randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases
    Schrader, A. J.
    Nilsson, S.
    Sartor, O.
    Bruland, O.
    Fang, F.
    Aksnes, A. K.
    Parker, C.
    ONKOLOGIE, 2013, 36 : 17 - 18
  • [7] Pain analyses from the phase 3 randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases
    Schrader, A. J.
    Nilsson, S.
    Sartor, O.
    Bruland, O.
    Fang, F.
    Aksnes, A-K
    Parker, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 59 - 59
  • [8] Efficacy and safety of radium-223 dichloride (Ra-223) in castration-resistant prostate cancer (CRPC) patients with bone metastases who had prior or no-prior docetaxel in the phase 3 ALSYMPCA trial
    Koenig, F.
    Vogelzang, N. J.
    Helle, S. I.
    Johannessen, D. C.
    O'Sullivan, J. M.
    Garcia-Vargas, J.
    Tear, C. G. O'Bryan
    Shan, M.
    Parker, C.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 59 - 59
  • [9] Pain analysis from the phase III randomized ALSYMPCA study with radium-223 dichloride (Ra-223) in patients with castration-resistant prostate cancer (CRPC) with bone metastases
    Nilsson, Sten
    Sartor, A. Oliver
    Bruland, Oyvind S.
    Fang, Fang
    Aksnes, Anne-Kirsti
    Parker, Chris
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06)
  • [10] Hematologic safety of Ra-223 dichloride (Ra-223) in castration- resistant prostate cancer (CRPC) patients with bone metastases from the phase 3 ALSYMPCA trial
    Strauss, A.
    Parker, C.
    Garcia-Vargas, J.
    O'Bryan-Tear, C. G.
    Fang, F.
    Vogelzang, N. J.
    ONCOLOGY RESEARCH AND TREATMENT, 2014, 37 : 59 - 60
12345